Progenics Pharmaceuticals (PGNX) : Traders are bullish on Progenics Pharmaceuticals (PGNX) as it has outperformed the S&P 500 by a margin of 25.66% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 17.12%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 17.84% in the last 1 week, and is up 34.15% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Progenics Pharmaceuticals (NASDAQ:PGNX): The stock opened at $6.21 on Friday but the bulls could not build on the opening and the stock topped out at $6.25 for the day. The stock traded down to $5.96 during the day, due to lack of any buying support eventually closed down at $6.01 with a loss of -2.44% for the day. The stock had closed at $6.16 on the previous day. The total traded volume was 1,959,216 shares.
The stock has recorded a 20-day Moving Average of 21.39% and the 50-Day Moving Average is 24.04%. Progenics Pharmaceuticals, Inc. is up 8.68% in the last 3-month period. Year-to-Date the stock performance stands at -1.96%.
Progenics Pharmaceuticals, Inc.is engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).